166 related articles for article (PubMed ID: 21633514)
1. Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006.
Beck EJ; Mandalia S; Lo G; Sharott P; Youle M; Anderson J; Baily G; Brettle R; Fisher M; Gompels M; Kinghorn G; Johnson M; McCarron B; Pozniak A; Tang A; Walsh J; White D; Williams I; Gazzard B;
PLoS One; 2011; 6(5):e20200. PubMed ID: 21633514
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.
Beck EJ; Mandalia S; Sangha R; Sharott P; Youle M; Baily G; Brettle R; Gompels M; Johnson M; McCarron B; Ong E; Pozniak A; Schwenk A; Taylor S; Walsh J; Wilkins E; Williams I; Gazzard B;
PLoS One; 2011; 6(12):e27830. PubMed ID: 22194795
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
4. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
[TBL] [Abstract][Full Text] [Related]
5. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C; d'Arminio-Monforte A; Pozniak AL; Lapadula G; Cologni G; Antinori A; De Luca A; Mussini C; Castagna A; Cicconi P; Minoli L; Costantini A; Carosi G; Liang H; Cesana BM;
BMC Infect Dis; 2011 Jan; 11():23. PubMed ID: 21266068
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
7. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.
Aragão F; Vera J; Vaz Pinto I
PLoS One; 2012; 7(9):e44774. PubMed ID: 23028618
[TBL] [Abstract][Full Text] [Related]
9. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.
Klein MB; Willemot P; Murphy T; Lalonde RG
AIDS; 2004 Sep; 18(14):1895-904. PubMed ID: 15353975
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
Waters L; Stebbing J; Jones R; Michailidis C; Sawleshwarkar S; Mandalia S; Bower M; Nelson M; Gazzard B
J Antimicrob Chemother; 2004 Aug; 54(2):503-7. PubMed ID: 15201230
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
12. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
Bendavid E; Wood R; Katzenstein DA; Bayoumi AM; Owens DK
J Acquir Immune Defic Syndr; 2009 Sep; 52(1):106-13. PubMed ID: 19448557
[TBL] [Abstract][Full Text] [Related]
13. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
14. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
[TBL] [Abstract][Full Text] [Related]
16. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
[TBL] [Abstract][Full Text] [Related]
17. Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.
Bunupuradah T; Puthanakit T; Fahey P; Kariminia A; Yusoff NK; Khanh TH; Sohn AH; Chokephaibulkit K; Lumbiganon P; Hansudewechakul R; Razali K; Kurniati N; Huy BV; Sudjaritruk T; Kumarasamy N; Fong SM; Saphonn V; Ananworanich J;
Antivir Ther; 2013; 18(4):591-8. PubMed ID: 23296119
[TBL] [Abstract][Full Text] [Related]
18. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.
Manfredi R; Calza L; Chiodo F
J Antimicrob Chemother; 2002 May; 49(5):723-9. PubMed ID: 12003964
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
20. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]